Gilead Sciences has announced to purchase an Immuno-oncology company Forty Seven for USD 95.50 per share, totalling up to a deal value of USD 4.9 billion. Akrevia Therapeutics has rebranded itself as Xilio Therapeutics, after two years of its launch. New York-based Cerovene has announced the recommendation from the US FDA to its pyrimethamine for curing toxoplasmosis. For more details visit: https://www.delveinsight.com/blog/recent-pharma-happenings-for-gilead-akrevia-xilio-cerovene/